BioMedNewsBreaks — Black Hawk Acquisition Corporation (Nasdaq: BKHA) SPAC Target Vesicor Therapeutics Names Michael Tolentino CEO

Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR) announced that its proposed de-SPAC acquisition target, Vesicor Therapeutics Inc., has appointed Michael Tolentino, M.D., as chief executive officer effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who will transition to chief scientific officer as the company advances its p53-based cancer therapeutic platform and prepares for IND-enabling studies and a planned FDA submission. Dr. Tolentino brings more than 20 years of biotechnology leadership experience spanning drug discovery, clinical development and company building, including roles in the development of Avastin and leadership positions at multiple biotech firms, and is expected to support execution of Vesicor growth strategy and progression toward its proposed merger with Black Hawk Acquisition Corporation.

To view the full press release, visit https://ibn.fm/MrtXg

About Black Hawk Acquisition Corporation

Black Hawk Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region.

For more information on the Company, please visit https://www.bhspac.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN